TY - JOUR
T1 - Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death
AU - Gonçalves, António Pedro
AU - Videira, Arnaldo
AU - Máximo, Valdemar
AU - Soares, Paula
N1 - Funding Information:
We thank Vitor Trovisco. APG was recipient of a fellowship from Fundação Calouste Gulbenkian (reference 104210). IBMC and IPATIMUP are Associated Laboratories of the Portuguese Ministry of Science, Technology and Higher Education, and is partially supported by from the Portuguese Foundation for Science and Technology.
PY - 2011/9
Y1 - 2011/9
N2 - TPC-1 is a highly proliferative thyroid papillary carcinoma-derived cell line. These cells express the RET/PTC1 fusion protein, whose isoforms are characterized in this work. The bacterial alkaloid staurosporine and the plant extract rotenone are death-inducing drugs that have an inhibitory synergistic effect on the growth of TPC-1 cells. We show that this synergism is accompanied by an enhancement of the induction of cell death. Staurosporine alone induces cell cycle arrest in G 1, whereas rotenone induces arrest in G 2/M. We suggest that this additive pressure may drive cells to die, resulting in the synergistic interaction of the drug combination. These data emphasize the potential use of the staurosporine plus rotenone combination as an anticancer tool.
AB - TPC-1 is a highly proliferative thyroid papillary carcinoma-derived cell line. These cells express the RET/PTC1 fusion protein, whose isoforms are characterized in this work. The bacterial alkaloid staurosporine and the plant extract rotenone are death-inducing drugs that have an inhibitory synergistic effect on the growth of TPC-1 cells. We show that this synergism is accompanied by an enhancement of the induction of cell death. Staurosporine alone induces cell cycle arrest in G 1, whereas rotenone induces arrest in G 2/M. We suggest that this additive pressure may drive cells to die, resulting in the synergistic interaction of the drug combination. These data emphasize the potential use of the staurosporine plus rotenone combination as an anticancer tool.
UR - http://www.scopus.com/inward/record.url?scp=80054988937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054988937&partnerID=8YFLogxK
U2 - 10.1007/s12038-011-9100-7
DO - 10.1007/s12038-011-9100-7
M3 - Article
C2 - 21857110
AN - SCOPUS:80054988937
SN - 0250-5991
VL - 36
SP - 639
EP - 648
JO - Journal of Biosciences
JF - Journal of Biosciences
IS - 4
ER -
